GRITSTONE ONCOLOGY INC's ticker is GRTS and the CUSIP is 39868T105. A total of 53 filers reported holding GRITSTONE ONCOLOGY INC in Q4 2018. The put-call ratio across all filers is - and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,467 | -11.8% | 7,248 | 0.0% | 0.00% | -100.0% |
| Q2 2023 | $14,134 | +1.0% | 7,248 | +119.5% | 0.00% | 0.0% |
| Q1 2022 | $14,000 | -66.7% | 3,302 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $42,000 | +55.6% | 3,302 | +29.7% | 0.00% | 0.0% |
| Q3 2021 | $27,000 | +17.4% | 2,546 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $23,000 | -4.2% | 2,546 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $24,000 | +166.7% | 2,546 | +17.0% | 0.00% | – |
| Q4 2020 | $9,000 | +50.0% | 2,176 | 0.0% | 0.00% | – |
| Q3 2020 | $6,000 | -57.1% | 2,176 | 0.0% | 0.00% | -100.0% |
| Q2 2020 | $14,000 | +7.7% | 2,176 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $13,000 | -35.0% | 2,176 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $20,000 | +5.3% | 2,176 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $19,000 | -20.8% | 2,176 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $24,000 | +200.0% | 2,176 | +281.8% | 0.00% | – |
| Q1 2019 | $8,000 | -11.1% | 570 | 0.0% | 0.00% | – |
| Q4 2018 | $9,000 | – | 570 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 4,450,638 | $41,970,000 | 8.18% |
| Copernicus Capital Management, LLC | 37,000 | $349,000 | 5.64% |
| EcoR1 Capital, LLC | 3,421,287 | $32,263,000 | 1.43% |
| Palo Alto Investors LP | 2,298,382 | $21,674,000 | 1.24% |
| AlpInvest Partners B.V. | 226,866 | $2,139,000 | 1.06% |
| Stenahm Asset Managment Ltd | 150,000 | $1,415,000 | 1.00% |
| FRAZIER MANAGEMENT LLC | 1,030,878 | $9,721,000 | 0.78% |
| BVF INC/IL | 1,861,239 | $17,551,000 | 0.66% |
| Avidity Partners Management LP | 2,122,064 | $20,011,000 | 0.55% |
| Redmile Group, LLC | 2,448,158 | $23,086,000 | 0.32% |